Deutsche Bank is out with a research report this morning, where it reiterates its Hold rating on LHC Group Inc. LHCG; it has a $34.00 price target on the stock.
The DB analysts cited the recent Medicate rate cut for its further downside revision to estimates. The analysts are maintaining their positive bias on LHCG's fundamentals, though.
The analysts believe the company is increasingly positioned as a leader from its investments in technology and infrastructure, while its JV strategy could further establish LHCG as a partner-of-choice as hospitals develop post-acute models for ACOs and/or bundled payments in the future.
As for valuation the DB analysts remarked, “Our $34 12-month valuation target is based on 6.5x 2012 EV/EBITDA, which is a discount to the 7x forward EV/EBITDA multiple of our coverage universe due to regulatory risks.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in